Angion Biomedica Corp.
51 Charles Lindbergh Boulevard
Uniondale, New York 11553
February 2, 2021
VIA EDGAR AND E-MAIL
United States Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549-6010
Attention: Tonya K. Aldave
Re: Angion Biomedica Corp. Registration Statement on Form S-1 (Registration No. 333-252177)
Ladies and Gentlemen:
In accordance with Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, we hereby request acceleration of the effective date of the Registration Statement on Form S-1 (File No. 333-252177) (the “Registration Statement”) of Angion Biomedica Corp. (the “Company”). We respectfully request that the Registration Statement become effective as of 4:00 p.m., Washington, D.C. time, on February 4, 2021, or as soon as practicable thereafter, or at such other time thereafter as our counsel, Latham & Watkins LLP may request by telephone. Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Latham & Watkins LLP, by calling Miles Jennings at (650) 328-4600.
Thank you for your assistance in this matter.
| Very truly yours, | |
|
| |
| ANGION BIOMEDICA CORP. | |
|
|
|
| By: | /s/ Jay Venkatesan |
|
| Jay Venkatesan |
|
| President and Chief Executive Officer |
CC: Jennifer Rhodes, Angion Biomedica Corp.
Patrick Pohlen, Latham & Watkins LLP
Miles Jennings, Latham & Watkins LLP
Kenneth Guernsey, Cooley LLP
Jonie Kondracki, Cooley LLP
